Logo Image
|Videos|September 16, 2017

Latest Results of the Population-Based HIV Impact Assessment Project

Author(s)Contagion

Jessica Justman, MD, reveals the latest results of the Population-based HIV Impact Assessment Project (2017).

Jessica Justman, MD, senior technical director, ICAP, Mailman School of Public Health & associate professor of medicine in epidemiology, Columbia University reveals the latest results of the Population-based HIV Impact Assessment Project (2017). Dr. Justman shares that she does not believe that a HIV vaccine is necessarily needed to achieve to 90-90-90 targets, as we these goals have almost been reached in certain countries. Dr. Justman also calls to attention that the biggest challenges have to do with adolescents and young adults.

Related to this article

View more
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more